Floatz logo

Monomethyl Fumarate

Blastic Plasmacytoid Dendritic Cell Neoplasm

Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Blastic Plasmacytoid Dendritic Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
Venetoclax
French Innovative Leukemia Organisation
Phase 2B
Busulphan
Fred Hutchinson Cancer Center
Phase 2B

View all 24 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →